MicroRNA-binding site SNPs in deregulated genes are associated with clinical outcome of non-small cell lung cancer

Lung Cancer

Volumn 85, Issue 3, 2014, Pages 442-448

  Xu, Jiali ^a   Tian, Shengwang ^b   Yin, Zhiqiang ^a   Wu, Shuangshuang ^a   Liu, Lingxiang ^a   Qian, Yingying ^a   Pei, Dong ^a   Gao, Wen ^a   Xu, Jing ^a   Yin, Yongmei ^a   Liu, Ping ^a   Shu, Yongqian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b China   (China)

Author keywords

Biomarker; Chemotherapy; MiRNA; Non small cell lung cancer; Outcome; Polymorphism; Survival

Indexed keywords

BRCA1 PROTEIN; CDH5 PROTEIN; FLAP ENDONUCLEASE; GLUCOSE TRANSPORTER 1; HISTONE DEACETYLASE 2; MICA PROTEIN; MICRORNA; MICRORNA 1202; MICRORNA 1236; MICRORNA 1248; MICRORNA 1250; MICRORNA 1262; MICRORNA 1825; MICRORNA 192; MICRORNA 215; MICRORNA 298; MICRORNA 342 5P; MICRORNA 365; MICRORNA 429; MICRORNA 490 3P; MICRORNA 544; MICRORNA 588; MICRORNA 619; MICRORNA 621; MICRORNA 656; MICRORNA 944; PLATINUM; PROTEIN; SOMATOMEDIN C RECEPTOR; TYMS PROTEIN; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; ANTINEOPLASTIC AGENT; MESSENGER RNA;

ADVANCED CANCER; ALLELE; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG RESPONSE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC REGULATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE MAP; HUMAN; IN VITRO STUDY; LOGISTIC REGRESSION ANALYSIS; LUCIFERASE ASSAY; LUNG SURGERY; MAJOR CLINICAL STUDY; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT RISK; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; QUANTITATIVE TRAIT LOCUS; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; 3' UNTRANSLATED REGION; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; FOLLOW UP; GENETIC TRANSFECTION; GENETICS; LUNG NEOPLASMS; MORTALITY; NUCLEOTIDE SEQUENCE; PROGNOSIS; REPORTER GENE; RNA INTERFERENCE; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ALLELES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE SEQUENCE; BINDING SITES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FOLLOW-UP STUDIES; GENES, REPORTER; HUMANS; LUNG NEOPLASMS; MICRORNAS; PATIENT OUTCOME ASSESSMENT; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RNA INTERFERENCE; RNA, MESSENGER; TRANSFECTION;

EID: 84926422229     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.06.010     Document Type: Article

References (45)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Yang L., Parkin D.M., Li L., Chen Y. Time trends in cancer mortality in China: 1987-1999. Int J Cancer 2003, 106:771-783.
3. Bahl A., Falk S. Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know. Br J Cancer 2001, 84:1143-1145.
4. Ludwig J.A., Weinstein J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005, 5:845-856.
5. Sweeney C., Nazar-Stewart V., Stapleton P.L., Eaton D.L., Vaughan T.L. Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev 2003, 12:527-533.
6. Gurubhagavatula S., Liu G., Park S., Zhou W., Su L., Wain J.C., et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004, 22:2594-2601.
7. Shintani Y., Ohta M., Hirabayashi H., Tanaka H., Iuchi K., Nakagawa K., et al. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer 2003, 104:790-795.
8. Busche A., Goldmann T., Naumann U., Steinle A., Brandau S. Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene A. Hum Gene Ther 2006, 17:135-146.
9. Nikolova T., Christmann M., Kaina B. FEN1 is overexpressed in testis, lung and brain tumors. Anticancer Res 2009, 29:2453-2459.
10. Jung K.H., Noh J.H., Kim J.K., Eun J.W., Bae H.J., Xie H.J., et al. HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins. J Cell Biochem 2012, 113:2167-2177.
11. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
12. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
13. Carthew R.W. Gene regulation by microRNAs. Curr Opin Genet Dev 2006, 16:203-208.
14. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269.
15. Ryan B.M., Robles A.I., Harris C.C. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010, 10:389-402.
16. Xing J., Wan S., Zhou F., Qu F., Li B., Myers R.E., et al. Genetic polymorphisms in pre-microRNA genes as prognostic markers of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2012, 21:217-227.
17. Wang K., Li J., Guo H., Xu X., Xiong G., Guan X., et al. MiR-196a binding-site SNP regulates RAP1A expression contributing to esophageal squamous cell carcinoma risk and metastasis. Carcinogenesis 2012, 33:2147-2154.
18. Xu J., Yin Z., Gao W., Liu L., Yin Y., Liu P., et al. Genetic variation in a MicroRNA-502 binding site in SET8 gene confers clinical outcome of non-small cell lung cancer in a Chinese population. PLoS ONE 2013, 8:e77024.
19. Kao S., Shiau C.K., Gu D.L., Ho C.M., Su W.H., Chen C.F., et al. IGDB.NSCLC: integrated genomic database of non-small cell lung cancer. Nucleic Acids Res 2012, 40:D972-D977.
20. Xu Z., Taylor J.A. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res 2009, 37:W600-W605.
21. Holm K., Melum E., Franke A., Karlsen T.H. SNPexp - a web tool for calculating and visualizing correlation between HapMap genotypes and gene expression levels. BMC Bioinformatics 2010, 11:600.
22. Stranger B.E., Forrest M.S., Dunning M., Ingle C.E., Beazley C., Thorne N., et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 2007, 315:848-853.
23. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
24. Mazumder B., Seshadri V., Fox P.L. Translational control by the 3'-UTR: the ends specify the means. Trends Biochem Sci 2003, 28:91-98.
25. Chen M., Rahman L., Voeller D., Kastanos E., Yang S.X., Feigenbaum L., et al. Transgenic expression of human thymidylate synthase accelerates the development of hyperplasia and tumors in the endocrine pancreas. Oncogene 2007, 26:4817-4824.
26. Pestalozzi B.C., Peterson H.F., Gelber R.D., Goldhirsch A., Gusterson B.A., Trihia H., et al. Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 1997, 15:1923-1931.
27. Nomura T., Nakagawa M., Fujita Y., Hanada T., Mimata H., Nomura Y. Clinical significance of thymidylate synthase expression in bladder cancer. Int J Urol 2002, 9:368-376.
28. Suzuki M., Tsukagoshi S., Saga Y., Ohwada M., Sato I. Enhanced expression of thymidylate synthase may be of prognostic importance in advanced cervical cancer. Oncology 1999, 57:50-54.
29. Zheng Z., Li X., Schell M.J., Chen T., Boulware D., Robinson L., et al. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer 2008, 112:2765-2773.
30. Cui L.H., Yu Z., Zhang T.T., Shin M.H., Kim H.N., Choi J.S. Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC. Pharmacogenomics 2011, 12:797-808.
31. Wang J., Wang B., Bi J., Di J. The association between two polymorphisms in the TYMS gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2011, 128:203-209.
32. Moore L.E., Hung R., Karami S., Boffetta P., Berndt S., Hsu C.C., et al. Folate metabolism genes, vegetable intake and renal cancer risk in central Europe. Int J Cancer 2008, 122:1710-1715.
33. Saviozzi S., Ceppi P., Novello S., Ghio P., Lo Iacono M., Borasio P., et al. Non-small cell lung cancer exhibits transcript overexpression of genes associated with homologous recombination and DNA replication pathways. Cancer Res 2009, 69:3390-3396.
34. Nicolson M.C., Fennell D.A., Ferry D., O'Byrne K., Shah R., Potter V., et al. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. J Thorac Oncol 2013, 8:930-939.
35. Borczuk A.C., Gorenstein L., Walter K.L., Assaad A.A., Wang L., Powell C.A. Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol 2003, 163:1949-1960.
36. Ozdag H., Teschendorff A.E., Ahmed A.A., Hyland S.J., Blenkiron C., Bobrow L., et al. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 2006, 7:90.
37. Quint K., Agaimy A., Di Fazio P., Montalbano R., Steindorf C., Jung R., et al. Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch 2011, 459:129-139.
38. Noh J.H., Jung K.H., Kim J.K., Eun J.W., Bae H.J., Xie H.J., et al. Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins. PLoS ONE 2011, 6:e28103.
39. Yang Z., Zhou L., Wu L.M., Xie H.Y., Zhang F., Zheng S.S. Combination of polymorphisms within the HDAC1 and HDAC3 gene predict tumor recurrence in hepatocellular carcinoma patients that have undergone transplant therapy. Clin Chem Lab Med 2010, 48:1785-1791.
40. Lieber M.R. The FEN-1 family of structure-specific nucleases in eukaryotic DNA replication, recombination and repair. Bioessays 1997, 19:233-240.
41. Zheng L., Zhou M., Chai Q., Parrish J., Xue D., Patrick S.M., et al. Novel function of the flap endonuclease 1 complex in processing stalled DNA replication forks. EMBO Rep 2005, 6:83-89.
42. Reagan M.S., Pittenger C., Siede W., Friedberg E.C. Characterization of a mutant strain of Saccharomyces cerevisiae with a deletion of the RAD27 gene, a structural homolog of the RAD2 nucleotide excision repair gene. J Bacteriol 1995, 177:364-371.
43. Sato M., Girard L., Sekine I., Sunaga N., Ramirez R.D., Kamibayashi C., et al. Increased expression and no mutation of the Flap endonuclease (FEN1) gene in human lung cancer. Oncogene 2003, 22:7243-7246.
44. Yang M., Guo H., Wu C., He Y., Yu D., Zhou L., et al. Functional FEN1 polymorphisms are associated with DNA damage levels and lung cancer risk. Hum Mutat 2009, 30:1320-1328.
45. Chen D., Juko-Pecirep I., Hammer J., Ivansson E., Enroth S., Gustavsson I., et al. Genome-wide association study of susceptibility loci for cervical cancer. J Natl Cancer Inst 2013, 105:624-633.